Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy

Amer M. Zeidan, Jan Philipp Bewersdorf, Vanessa E. Gray, Rory M. Shallis, Ethan Thompson, Daniel L. Menezes, Shelonidta Rose, Isaac W. Boss, Stephanie Halene, Torsten Haferlach, Brian A. Fox